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INTRODUCTION
oronavirus disease 2019 (COVID-19) is a pandemic
caused by a novel coronavirus that has been
identiﬁed to belong to the b-coronavirus family.1 As
the COVID-19 pandemic continues to evolve, more aspects of this illness are being deﬁned and described. In
the United States, the incidence of acute kidney injury
(AKI) in patients hospitalized with COVID-19 has been
reported to be around 37%.2 Different autopsy and
kidney biopsy series have revealed acute tubular
injury (ATI) to be the most common renal pathology
lesion in these patients.3,S1
Although cases of collapsing glomerulopathy and
thrombotic microangiopathy (TMA) with COVID-19
have been reported,4,5 an association between COVID19 and crescentic glomerulonephritis (GN) has rarely
been described.6 Herein, we report 2 cases of pauci
immune GN with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection, who clinically
improved with treatment of COVID-19 and cautious use
of immunosuppressants.

C

CASE PRESENTATION
Case 1
A 64-year-old African American man with a remote
history of cryptogenic organizing pneumonia presented to the hospital with 2 weeks of progressive
shortness of breath and dry cough. There was no history of fever or sick contacts. He was noted to be in
Kidney International Reports (2020) 5, 2079–2083

hypoxic respiratory failure, with a respiratory rate of
23, and low oxygen saturation of 83% on room air,
which improved to 100% on a 10-L non-rebreather
mask. Otherwise, the patient was hemodynamically
stable and afebrile. Laboratory ﬁndings revealed AKI
with elevated serum creatinine (SCr) of 7.87 mg/dl
(baseline SCr was unknown), and elevated inﬂammatory markers D-dimer 1353 ng/ml, ferritin 1985 ng/ml,
and C-reactive protein 14.53 mg/dl. He was diagnosed
with COVID-19 using reverse transcription
polymerase chain reaction (RT-PCR) assay for SARSCoV-2 on a nasopharyngeal swab; chest x-ray showed
bilateral patchy opacities. Urinalysis revealed an active
sediment with 55 red blood cells per high-power ﬁeld,
65 white blood cells per high-power ﬁeld, and signiﬁcant proteinuria, with spot urine protein-to-creatinine
ratio elevated at 5. Serum albumin was low at 2.8 g/
dl. His respiratory status and kidney function progressively worsened, despite use of high-dose i.v. diuretics. The patient was initiated on intermittent
hemodialysis treatment to optimize his condition for
kidney biopsy, as well as to assist with volume overload and electrolyte derangements. COVID-19 was
treated with convalescent plasma and intravenous
tocilizumab, with negligible improvement in respiratory status. Serologies revealed normal serum complements (C3 and C4), a high perinuclear antineutrophilic
autoantibody (p-ANCA) titer (1:640) with a speciﬁc
anti myeloperoxidase antibody (MPO) titer of 32.5
units/ml, positive antinuclear antibody (1:160,
2079
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Figure 1. Kidney biopsy ﬁndings. (a) Two glomeruli in the center reveal crescents: a cellular crescent in the glomerulus to the left, and a
ﬁbrocellular crescent to the right. Surrounding tubules reveal distension and ﬂattening of the epithelium (periodic acid Schiff stain, original
magniﬁcation 200). (b) Immunoﬂuorescence staining for IgG reveals no signiﬁcant staining in depicted glomerulus or surrounding tubular
basement membranes (ﬂuorescein isothiocyanate, original magniﬁcation 200). (c) Representative section showing negative immunohistochemistry staining for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein after antigen retrieval (original
magniﬁcation 200). (d) Lung tissue from a known SARS-CoV-2 infected patient served as positive control for immunohistochemistry method
(original magniﬁcation 400).

homogenous pattern), anti double strand DNA antibody of 112 IU/ml, and anti-ribonuclear protein (RNP)
antibody of 1.1 AI. Anti glomerular basement membrane antibody (anti-GBM) was not detected. A kidney
biopsy was subsequently performed.
Kidney Biopsy Findings

A total of 10 glomeruli were seen on light microscopy;
4 glomeruli showed small cellular crescents and/or
segmental necrosis, and 3 contained ﬁbrocellular
(healing) crescents. There was moderate acute tubular
necrosis. Immunohistochemistry staining for SARSCoV-2 was negative. Immunoﬂuorescence microscopy
revealed nonspeciﬁc ﬁndings (Figure 1). On electron
microscopy, there were no electron-dense deposits, and
no viral particles were seen. (This case has been brieﬂy
described with emphasis on kidney biopsy ﬁndings, as
a part of kidney biopsy series.7)

by a dose of i.v. rituximab at a 1000-mg dose once the
COVID-19 PCR result turned negative.
Clinical Outcome

The patient did not require mechanical ventilation. His
kidney function started to improve after use of pulse
dose corticosteroids, and hemodialysis was discontinued. Serum creatinine initially decreased and
stabilized at 3.5 mg/dl; however, the hospital course
was complicated by methicillin-sensitive Staphylococcus
aureus bacteremia with new AKI, when SCr peaked at
4.89 mg/dl. The patient remained non-oliguric, with a
decrease in SCr to 4.1 mg/dl and an MPO titer to 14
units/ml upon discharge. His SCr continues to decrease
and has improved to 2.41 mg/dl approximately 1
month after receipt of rituximab. He is scheduled to
receive a second dose of rituximab at completion of
antibiotic therapy for bacteremia.

Clinicopathologic Diagnosis

The clinicopatholic diagnosis was pauci-immune crescentic glomerulonephritis, in the setting of MPOANCA vasculitis.
Treatment

The patient received i.v. pulse dose corticosteroids (500
mg i.v. methylprednisolone daily for 3 days), followed
2080

Case 2
A 46-year-old South Asian man with diabetes mellitus
presented with fever, cough, diffuse purpuric rash,
and AKI with an SCr of 2.9 mg/dl on admission. A few
days prior, he was treated for pneumonia with azithromycin. The RT-PCR for SARS-CoV-2 was positive
Kidney International Reports (2020) 5, 2079–2083

NEPHROLOGY ROUNDS

c-ANCA, cytoplasmic antineutrophilic autoantibody; COVID-19, coronavirus disease 2019; GN, glomerulonephritis; p-ANCA, perinuclear antineutrophilic autoantibody; MPO, myeloperoxidase; NA: Not available; PR3, proteinase 3; Ref, reference; SCr,
serum creatinine.

NA
c-ANCA (1:50)
Hydroxychloroquine, levoﬂoxacin,
i.v. Ig
5.5
25 Male Iranian
Ref 6

None

NA

c-ANCA

Alveolar hemorrhage

None

Crescentic
GN

No

Glucocorticoids,
cyclophosphamide,
plasmapheresis

PR-3: 28.8
U/ml
PR-3: 57.3
U/ml
Hydroxychloroquine, azithromycin
4.0
South
Asian
46 Male
2

Diabetes
mellitus

2.1 g/dl

PR3
Resolving peripheral Leukocytoclastic
Focal
(c-ANCA) ground glass opacities
vasculitis
necrotizing
GN

No

Glucocorticoids, rituximab

MPO: 14
U/ml
MPO: 32.5
U/ml
Glucocorticoids, rituximab
Tocilizumab, convalescent
plasma
Yes,
hemodialysis
Crescentic
GN
None
7.87
64 Male African
American
1

None

2.8 g/dl

MPO
(p-ANCA)

Bilateral patchy
inﬁltrates

COVID-19 treatment
Skin pathology
Lung involvement

Renal
replacement
therapy
Kidney
pathology
Case Age
Peak SCr Serum Positive
no.
(yr) Sex Ethnicity Comorbidities (mg/dl) albumin serology

Table 1. Patient demographics, clinical ﬁndings, treatment, and outcomes

AAV treatment

Antibody titers Antibody titers 2 wk
on admission
after rituximab
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on nasopharyngeal swab, conﬁrming the diagnosis of
COVID-19, and he was initiated on hydroxychloroquine. Urinalysis showed 100 mg/dl of protein
and moderate blood. Serum albumin was low at 2.1 g/
dl. A skin biopsy revealed leukocytoclastic vasculitis.
Kidney function worsened, with a peak SCr of 4.0 mg/
dl. Serological evaluation for glomerular disease
showed normal serum C3 and C4, an elevated proteinase 3 (PR3) level of 57.3 units/ml, elevated rheumatoid
factor (320 IU/ml), and IgG kappa monoclonal band on
serum immunoﬁxation. A kidney biopsy was
performed.
Kidney Biopsy Findings

Kidney biopsy ﬁndings were focal necrotizing
glomerulonephritis with segmental glomerular
thrombi, diffuse severe tubular epithelial injury, mild
interstitial ﬁbrosis, and moderate arteriosclerosis.
Immunoﬂuorescence microscopy showed trace
segmental, ﬁnely granular, and mostly mesangial
staining for IgA, IgM, and C3. No signiﬁcant staining
for IgG, C1q, kappa, or lambda light chains was noted.
Rare mesangial dense deposits were seen on electron
microscopy, but no viral particles were noted.
Clinicopathologic Diagnosis

The
clinicopathologic
diagnosis
was
PR3ANCA associated vasculitis (AAV) with focal necrotizing, pauci-immune glomerulonephritis.
Treatment

The patient was initiated on pulse dose corticosteroids
(i.v. methylprednisolone, given as 1 g daily for 3 days)
and received the ﬁrst dose of rituximab (375 mg/m2
i.v.) during the hospital stay. Subsequently, he was
transitioned to oral prednisone and completed his rituximab treatment after discharge.
Clinical Outcome

Two weeks after the initial dose of rituximab, the patient’s PR3 titer decreased to 28.8 units/ml, and SCr
improved to 2.0 mg/dl. The most recent urinalysis has
been negative for protein, with mild hematuria. The
SCr has decreased to 1.27 mg/dl, at 12 weeks after
initial diagnosis.
Table 1 summarizes clinical ﬁndings, demographics,
and treatment strategies of our 2 cases and the alreadypublished case6 of ANCA-associated GN with COVID-19.
DISCUSSION
Several mechanisms for the development of kidney
injury in COVID-19 patients, including hemodynamic
factors, viral tropism toward kidney tissue,8 and
endothelial dysfunction leading to ﬁbrinoid necrosis
and development of micro thrombi, have been postulated.9 In addition to the direct cytopathic effect of
2081
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SARS-CoV-2 on the glomeruli and renal tubules, there
is also the indirect effect of cell-mediated immunity,
the cytokine storm, and the cross-talk between organs,
with possible systemic effects of the disease.S2
A series of publications have reported the development of a vasculitis-like illness in COVID-19 patients,
with presentations ranging from vasculitis syndromesS3
to histologic ﬁndings of vasculitis seen on post mortem
examination.S4
We describe 2 patients with ANCA-associated GN
and severe AKI associated with COVID-19. Both patients are nonobese men, without any prior history of
kidney disease or known ANCA vasculitis. The pulmonary ﬁndings in our 2 patients were deemed to be
associated with COVID-19 illness and volume overload.
Clinically, pulmonary ANCA disease was not suspected.
Another case of cytoplasmic (c) ANCA associated with
glomerulonephritis in the setting of COVID-19 has been
reported in a 25-year-old man from Iran.6
Although the association between SARS-CoV-2
infection and our patients with GN remains obscure,
it is possible that cytokine storm, with immune
system related dysregulation in a uremic state, may
have led to an altered response to infection (similar to
the mechanism previously postulated for SARS-CoV
infection),S5 further giving rise to AAV. In addition,
it is possible that a speciﬁc host is prone to a certain
type of kidney pathology in response to a “second hit.”
Here, we postulate that the second hit is COVID-19.
Both MPO and PR3 are enzymes present on neutrophils, and autoantibodies to these enzymes can lead
to pauci-immune GN, a mechanism previously
demonstrated in a murine model in which i.v. injection
of anti-MPO splenocyte resulted in the development of
GN.S6 More recently, the role of these antibodies has
been expanded with the evidence that neutrophil
extracellular traps (NETs) serve as a source of autoantigens presenting MPO and PR3 to the immune
system. The presence of NETs has been observed on
kidney biopsy samples of patients with AAV,S7 and is
postulated to be involved in COVID-19 pathogenesis.S8
Given the severity of renal AAV in our patients,
cyclophosphamide and rituximab were considered
standard-of-care treatment options in conjunction with
glucocorticoid therapy. Immunosuppression with
cyclophosphamide or rituximab during COVID-19
infection is rightfully of great concern in the medical
community, and there is limited knowledge on outcomes of COVID-19 in patients on these background
therapies. Rituximab leads to B-cell depletion and can
abrogate a prompt and efﬁcient antibody response to
facilitate faster recovery from the virus. In addition,
use of rituximab can lead to the inability to mount
antibodies to a potential vaccine as well. However, for
2082
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Table 2. Teaching points
1. Although acute tubular injury is the most common kidney pathology seen with SARS-CoV2 infection, ANCA-associated glomerulonephritis can be associated with COVID-19.
2. Patients who developed ANCA glomerulonephritis responded well to immunosuppressive agents including rituximab, and none of these patients had deterioration of
SARS-CoV-2 related disease.
3. ANCA vasculitis should be considered as a differential diagnosis of COVID-19 related
acute kidney injury, and may be effectively managed with use of immunosuppressants despite underlying infection.
ANCA, antineutrophilic autoantibody; COVID-19, coronavirus disease 2019; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.

our patients, rituximab was considered as the choice of
therapy based on its better tolerability and lesser side
effects. Emerging reports of COVID-19 patients who
had been receiving rituximab (or other anti-CD20
monoclonal antibodies) for their underlying immunemediated conditions have demonstrated that these patients do not seem to have a worse course or outcome
compared with those in the general population, with
some even suggesting that rituximab may forestall the
cytokine storm seen in COVID-19 and may improve
outcomes.S9 S11 Furthermore, early and higher levels of
antiviral antibody titers have been correlated with
increased mortality in COVID-19 patients,S12 and patients with X-linked agammaglobulinemia (XLA) who
suffer from full B-cell deﬁciency have shown full recovery from COVID-19 infection.S13
Anders et al.S14 suggest postponing maintenance rituximab during the surge of the pandemic to avoid not
only the unnecessary immunosuppression but also unnecessary contact with other potentially infected patients
and health personnel during the rituximab administration. Regardless, treatment might be still indicated in
certain clinical settings. Although our ﬁrst patient
received rituximab after his COVID-19 PCR result turned
negative (to promote recovery and to ensure immunologic
memory from COVID-19), the second patient received it
concurrently with corticosteroid therapy. Both of the
patients had improvement in their COVID-19 related
symptoms, as well as kidney recovery.
In summary, ANCA-associated GN can be associated
with COVID-19. Because of the lack of scientiﬁc evidence related to COVID-19, management of diverse
pathological entities arising in its setting is challenging.
The existing literature on viral infection related
ANCA vasculitis reveals favorable outcomes with
treatment of virus and ANCA disease using antiviral
agent and immunosuppression concurrently; however,
our major concern was worsening of infection with the
use of immunosuppression, as no speciﬁc agent has
been proved to be beneﬁcial in treating COVID-19. All
3 patients with COVID-19 (2 patients in this series and
1 previously published case6) who developed ANCA
glomerulonephritis responded well to immunosuppressive agents (Table 2). Interestingly, none of these
Kidney International Reports (2020) 5, 2079–2083
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patients had deterioration of SARS-CoV-2 related
disease. Further research is still necessary to determine
the optimal therapy for such conditions; however,
based on our experience, it is noteworthy that immunosuppression, when indicated, can be used in COVID19 patients, under close observation.
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